Imagine a world where a single treatment could manage type 2 diabetes or obesity for months at a time, freeing patients from the burden of daily medications and the frustrating cycle of weight regain. This isn’t a distant dream but a potential reality being shaped by Junevity, a biotechnology
What if a single batch of cells could save thousands of lives without the wait and expense of custom-made treatments? This isn’t a distant dream but a tangible reality unfolding in the realm of allogeneic cell therapy, where “off-the-shelf” solutions derived from donor cells are poised to
Imagine a world where the most abundant immune cells in the human body, crucial for fighting infections, remain a mysterious black box to scientists and medical professionals. For too long, neutrophils—those rapid-response warriors of the immune system—have been just that, with their complex
Imagine a world where life-saving drugs reach patients faster, with fewer animals harmed and costs slashed by millions. This isn’t a distant dream but a tangible goal as the U.S. Food and Drug Administration (FDA) pivots toward human-relevant drug safety models. With new draft guidance released
Diving into the intricate world of cancer biology, we’re thrilled to speak with Ivan Kairatov, a renowned biopharma expert with a profound background in research and development. With a sharp focus on technological innovation in the industry, Ivan has been at the forefront of uncovering how
Regulated bioprocesses rise or fall on the quiet details—additives, excipients, and media choices that shape every run and either unlock reproducibility or invite costly variability when scale-up and compliance converge. In that context, high‑purity methylcellulose has reemerged as a practical
